YangXueQingNaoWan attenuated blood brain barrier disruption after thrombolysis with tissue plasminogen activator in ischemia stroke

J Ethnopharmacol. 2024 Jan 10;318(Pt B):117024. doi: 10.1016/j.jep.2023.117024. Epub 2023 Aug 11.

Abstract

Ethnopharmacological relevant: YangXueQingNaoWan (YXQNW), a compound Chinese medicine, has been widely used for dizziness, irritability, insomnia, and dreaminess caused by blood deficiency and liver hyperactivity in China. However, whether YXQNW can inhibit cerebral microvascular exudation and cerebral hemorrhage (CH) caused by blood brain barrier (BBB) damage after tissue plasminogen activator (tPA) still unknown.

Aim of the research: To observe the effect of YXQNW on cerebral microvascular exudation and CH after tPA and investigate its mechanism in protecting BBB.

Materials and methods: Male C57BL/6 N mice suffered from ischemia stroke by mechanical detachment of carotid artery thrombi with the stimulation of ferric chloride. Then mice were treated with tPA (10 mg/kg) and/or YXQNW (0.72 g/kg) at 4.5 h. Cerebral blood flow (CBF), infarct size, survival rate, neurological scores, gait analysis, Evans blue extravasation, cerebral water content, fluorescein isothiocyanate-labeled albumin leakage, hemorrhage, junction and basement membrane proteins expression, leukocyte adhesion and matrix metalloproteinases (MMPs) expression were evaluated 24 h after tPA. Proteomics was used to identify target proteins.

Results: YXQNW inhibited cerebral infarction, neurobehavioral deficits, decreased survival, Evans blue leakage, albumin leakage, cerebral water content and CH after tPA thrombolysis; improved CBF, low-expression and degradation of junction proteins, basement membrane proteins, Arhgap21 and its downstream α-catenin and β-catenin proteins expression; and suppressed the increase of adherent leukocytes and the release of MMP-9 derived from macrophage.

Conclusion: YXQNW relieved BBB damage and attenuated cerebral microvascular exudation and CH after tPA thrombolysis. The effect of YXQNW on cerebral microvascular exudation was associated with the inhibition of the low-expression of junction proteins, especially AJs mediated by Rho GTPase-activating protein 21 (Arhgap21), while the effect on CH was associated with the inhibition of leukocyte adhesion, the release of MMP-9 derived from macrophage, and low-expression and degradation of collagen IV and laminin in the vascular basement membrane.

Keywords: Blood-brain barrier; Thrombus; Tissue plasminogen activator; YangXueQingNaoWan.

MeSH terms

  • Albumins / pharmacology
  • Animals
  • Blood-Brain Barrier
  • Brain Ischemia* / drug therapy
  • Brain Ischemia* / metabolism
  • Cerebral Hemorrhage / drug therapy
  • Cerebral Infarction / drug therapy
  • Evans Blue / metabolism
  • Evans Blue / pharmacology
  • Evans Blue / therapeutic use
  • Ischemic Stroke* / drug therapy
  • Male
  • Matrix Metalloproteinase 9 / metabolism
  • Mice
  • Mice, Inbred C57BL
  • Stroke* / drug therapy
  • Stroke* / metabolism
  • Thrombolytic Therapy
  • Tissue Plasminogen Activator / therapeutic use

Substances

  • Tissue Plasminogen Activator
  • Matrix Metalloproteinase 9
  • Evans Blue
  • Albumins